Micalcet

Cinacalcet hydrochloride, the active ingredient in Micalcet, is a calcimimetic presented as an oral tablet for oral use. It is used to treat secondary hyperparathyroidism in dialysis patients, primary hyperparathyroidism when surgery is not feasible, and hypercalcemia associated with parathyroid carcinoma.

GNH USA supplies Micalcet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for healthcare providers across multiple regions. Its distribution network ensures timely delivery and regulatory compliance.

Micalcet (cinacalcet) acts on the calcium‑sensing receptor pathway to control abnormal parathyroid hormone activity.

- Secondary hyperparathyroidism (CKD dialysis): lowers PTH levels and helps normalize serum calcium and phosphorus. - Primary hyperparathyroidism (non‑surgical): reduces PTH secretion when surgery is not an option. - Hypercalcemia associated with parathyroid carcinoma: decreases serum calcium by inhibiting PTH release.

Cinacalcet may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Muscle cramps

Serious or Rare Side Effects: - Severe hypocalcemia with risk of seizures or arrhythmia - Pancreatitis - Stevens‑Johnson syndrome or other severe skin reactions

When prescribing Micalcet, clinicians should observe several safety measures.

- Monitor serum calcium: check levels regularly to avoid hypocalcemia. - Monitor PTH levels: adjust dose based on therapeutic response. - Adjust dose in renal impairment: consider reduced clearance in severe kidney dysfunction. - Use with caution in pregnancy: safety not established, weigh benefits and risks. - Avoid in patients with known hypersensitivity to cinacalcet. - Store at room temperature: keep in original container, protect from moisture and light.

Cinacalcet interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase cinacalcet exposure. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): decrease cinacalcet effectiveness.

Moderate Interactions (Monitor Closely): - Vitamin D analogs and calcium supplements: may blunt calcium‑lowering effect. - Bisphosphonates: additive effect on calcium levels. - Loop diuretics: can enhance calcium loss. - ACE inhibitors: monitor blood pressure and renal function.